These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33042151)

  • 1. Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective.
    Khatri I; Staal FJT; van Dongen JJM
    Front Immunol; 2020; 11():570018. PubMed ID: 33042151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
    Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
    Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation.
    Hurlburt NK; Seydoux E; Wan YH; Edara VV; Stuart AB; Feng J; Suthar MS; McGuire AT; Stamatatos L; Pancera M
    Nat Commun; 2020 Oct; 11(1):5413. PubMed ID: 33110068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
    Papageorgiou AC; Mohsin I
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.
    Yuan M; Wu NC; Zhu X; Lee CD; So RTY; Lv H; Mok CKP; Wilson IA
    Science; 2020 May; 368(6491):630-633. PubMed ID: 32245784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.
    Corrêa Giron C; Laaksonen A; Barroso da Silva FL
    Virus Res; 2020 Aug; 285():198021. PubMed ID: 32416259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method.
    Lim H; Baek A; Kim J; Kim MS; Liu J; Nam KY; Yoon J; No KT
    Sci Rep; 2020 Oct; 10(1):16862. PubMed ID: 33033344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
    Shi R; Shan C; Duan X; Chen Z; Liu P; Song J; Song T; Bi X; Han C; Wu L; Gao G; Hu X; Zhang Y; Tong Z; Huang W; Liu WJ; Wu G; Zhang B; Wang L; Qi J; Feng H; Wang FS; Wang Q; Gao GF; Yuan Z; Yan J
    Nature; 2020 Aug; 584(7819):120-124. PubMed ID: 32454512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.
    Dong J; Huang B; Jia Z; Wang B; Gallolu Kankanamalage S; Titong A; Liu Y
    Emerg Microbes Infect; 2020 Dec; 9(1):1034-1036. PubMed ID: 32403995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
    Hansen J; Baum A; Pascal KE; Russo V; Giordano S; Wloga E; Fulton BO; Yan Y; Koon K; Patel K; Chung KM; Hermann A; Ullman E; Cruz J; Rafique A; Huang T; Fairhurst J; Libertiny C; Malbec M; Lee WY; Welsh R; Farr G; Pennington S; Deshpande D; Cheng J; Watty A; Bouffard P; Babb R; Levenkova N; Chen C; Zhang B; Romero Hernandez A; Saotome K; Zhou Y; Franklin M; Sivapalasingam S; Lye DC; Weston S; Logue J; Haupt R; Frieman M; Chen G; Olson W; Murphy AJ; Stahl N; Yancopoulos GD; Kyratsous CA
    Science; 2020 Aug; 369(6506):1010-1014. PubMed ID: 32540901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.
    Ejemel M; Li Q; Hou S; Schiller ZA; Tree JA; Wallace A; Amcheslavsky A; Kurt Yilmaz N; Buttigieg KR; Elmore MJ; Godwin K; Coombes N; Toomey JR; Schneider R; Ramchetty AS; Close BJ; Chen DY; Conway HL; Saeed M; Ganesa C; Carroll MW; Cavacini LA; Klempner MS; Schiffer CA; Wang Y
    Nat Commun; 2020 Aug; 11(1):4198. PubMed ID: 32826914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
    Kreye J; Reincke SM; Kornau HC; Sánchez-Sendin E; Corman VM; Liu H; Yuan M; Wu NC; Zhu X; Lee CD; Trimpert J; Höltje M; Dietert K; Stöffler L; von Wardenburg N; van Hoof S; Homeyer MA; Hoffmann J; Abdelgawad A; Gruber AD; Bertzbach LD; Vladimirova D; Li LY; Barthel PC; Skriner K; Hocke AC; Hippenstiel S; Witzenrath M; Suttorp N; Kurth F; Franke C; Endres M; Schmitz D; Jeworowski LM; Richter A; Schmidt ML; Schwarz T; Müller MA; Drosten C; Wendisch D; Sander LE; Osterrieder N; Wilson IA; Prüss H
    Cell; 2020 Nov; 183(4):1058-1069.e19. PubMed ID: 33058755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.